Cargando…

化疗对肺癌患者生活质量及焦虑情绪的影响及分析

BACKGROUND AND OBJECTIVE: This study aims to observe the changes in quality of life as well as the anxiety among lung cancer patients before and after chemotherapy. This work also aims to explore the effect of chemotherapy on quality of life and anxiety. METHODS: Fifty-eight lung cancer patients wer...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999953/
https://www.ncbi.nlm.nih.gov/pubmed/22901993
http://dx.doi.org/10.3779/j.issn.1009-3419.2012.08.03
_version_ 1783331567169437696
collection PubMed
description BACKGROUND AND OBJECTIVE: This study aims to observe the changes in quality of life as well as the anxiety among lung cancer patients before and after chemotherapy. This work also aims to explore the effect of chemotherapy on quality of life and anxiety. METHODS: Fifty-eight lung cancer patients were evaluated based on clinical outcomes, EORTC QLQ-C30, and on SAS questionnaires before chemotherapy, one week after two courses of chemotherapy, and one week after four courses of chemotherapy. RESULTS: Before chemotherapy, functioning scale, fatigue, and dyspnoea scores were high, the rate of anxiety was 56%, while the SAS score was 49.54±5.64. Anxiety was found to be positively correlated with insomnia (P < 0.05). After two courses of chemotherapy, dyspnoea scores decreased, while insomnia and appetite loss scores increased. The difference was statistically significant (P < 0.05). The rate of anxiety was 80%, and the SAS score was 52.48±6.10. The difference was statistically significant compared with that before chemotherapy (P < 0.05). The SAS scores of patients with disease history were higher than those of patients without disease history (P < 0.05). SAS score was found to be positively correlated with fatigue and dyspnoea (P < 0.05). After four courses of chemotherapy, the physical, role, emotional, and social function scores decreased, while the nausea and vomiting, appetite loss, constipation, and financial impact scores increased. The difference was statistically significant (P < 0.05). The anxiety rate was 72%, and the SAS score was 54.82±6.55. The difference was statistically significant (P < 0.05). The SAS score was negatively correlated with KPS (P < 0.05), significantly positively correlated with fatigue and insomnia (P < 0.01), and positively correlated with constipation (P < 0.05). CONCLUSION: A number of patients have experienced symptom relief, but during chemotherapy, the patients had significant anxiety. Thus, quality of life decreased. The quality of life and emotions of lung cancer patients should be evaluated, and positive psychological intervention should be given to improve quality of life.
format Online
Article
Text
id pubmed-5999953
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59999532018-07-06 化疗对肺癌患者生活质量及焦虑情绪的影响及分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: This study aims to observe the changes in quality of life as well as the anxiety among lung cancer patients before and after chemotherapy. This work also aims to explore the effect of chemotherapy on quality of life and anxiety. METHODS: Fifty-eight lung cancer patients were evaluated based on clinical outcomes, EORTC QLQ-C30, and on SAS questionnaires before chemotherapy, one week after two courses of chemotherapy, and one week after four courses of chemotherapy. RESULTS: Before chemotherapy, functioning scale, fatigue, and dyspnoea scores were high, the rate of anxiety was 56%, while the SAS score was 49.54±5.64. Anxiety was found to be positively correlated with insomnia (P < 0.05). After two courses of chemotherapy, dyspnoea scores decreased, while insomnia and appetite loss scores increased. The difference was statistically significant (P < 0.05). The rate of anxiety was 80%, and the SAS score was 52.48±6.10. The difference was statistically significant compared with that before chemotherapy (P < 0.05). The SAS scores of patients with disease history were higher than those of patients without disease history (P < 0.05). SAS score was found to be positively correlated with fatigue and dyspnoea (P < 0.05). After four courses of chemotherapy, the physical, role, emotional, and social function scores decreased, while the nausea and vomiting, appetite loss, constipation, and financial impact scores increased. The difference was statistically significant (P < 0.05). The anxiety rate was 72%, and the SAS score was 54.82±6.55. The difference was statistically significant (P < 0.05). The SAS score was negatively correlated with KPS (P < 0.05), significantly positively correlated with fatigue and insomnia (P < 0.01), and positively correlated with constipation (P < 0.05). CONCLUSION: A number of patients have experienced symptom relief, but during chemotherapy, the patients had significant anxiety. Thus, quality of life decreased. The quality of life and emotions of lung cancer patients should be evaluated, and positive psychological intervention should be given to improve quality of life. 中国肺癌杂志编辑部 2012-08-20 /pmc/articles/PMC5999953/ /pubmed/22901993 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.08.03 Text en 版权所有©《中国肺癌杂志》编辑部2012 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
化疗对肺癌患者生活质量及焦虑情绪的影响及分析
title 化疗对肺癌患者生活质量及焦虑情绪的影响及分析
title_full 化疗对肺癌患者生活质量及焦虑情绪的影响及分析
title_fullStr 化疗对肺癌患者生活质量及焦虑情绪的影响及分析
title_full_unstemmed 化疗对肺癌患者生活质量及焦虑情绪的影响及分析
title_short 化疗对肺癌患者生活质量及焦虑情绪的影响及分析
title_sort 化疗对肺癌患者生活质量及焦虑情绪的影响及分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999953/
https://www.ncbi.nlm.nih.gov/pubmed/22901993
http://dx.doi.org/10.3779/j.issn.1009-3419.2012.08.03
work_keys_str_mv AT huàliáoduìfèiáihuànzhěshēnghuózhìliàngjíjiāolǜqíngxùdeyǐngxiǎngjífēnxī
AT huàliáoduìfèiáihuànzhěshēnghuózhìliàngjíjiāolǜqíngxùdeyǐngxiǎngjífēnxī
AT huàliáoduìfèiáihuànzhěshēnghuózhìliàngjíjiāolǜqíngxùdeyǐngxiǎngjífēnxī
AT huàliáoduìfèiáihuànzhěshēnghuózhìliàngjíjiāolǜqíngxùdeyǐngxiǎngjífēnxī